There are no approved drug therapies for repigmentation in vitiligo but one could hit the market early next year in the form of Incyte Corporation's topical JAK inhibitor Opzelura, recently given the green light in the US for atopic dermatitis.
Dermatology To Become A Key Franchise For Incyte
Topical Formulation Of Ruxolitinib On Fast Track For Vitiligo
Having just launched Opzelura in the US for atopic dermatitis, the US biotech is hoping for another approval in the next few months for its topical JAK inhibitor, this time for vitiligo.
More from Dermatological
More from Therapy Areas
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.